Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofogliflozin and anagliptin monotherapy and combination therapy in type 2 diabetes
jRCTs031180440Completed
- Sponsor
- Kowa Company, Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of tofogliflozin and anagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Kowa Company, Ltd. Primary endpoint: Primary: Change in HbA1c from baseline to week 24. Started Mar 2018; status: completed.
02
Drugs
tofogliflozinanagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031180440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180440.